Novo Nordisk has filed a lawsuit against rival Eli Lilly (LLY), accusing the US drugmaker of running “false and misleading” advertisements for its obesity drug Zepbound. The legal clash between two of
More
Pharmaceutical supply chains face mounting pressure to maintain precise product traceability at every stage of the distribution process. Aggregation, the process of linking serialised items to their parent containers, has emerged as
More
A major legal divide has emerged between two Texas federal district courts over how to handle unconstitutional National Labor Relations Board removal protections. The central question is whether courts can sever the
More
The US Biglaw associate compensation market is moving fast, with firms rapidly matching a new $235K salary scale that Milbank first introduced on Tuesday, June 2, 2026. The new benchmark has triggered
More
Anti-DEI Group Files Fresh EEOC Charge Against Legal Industry Diversity Pipeline And 14 Biglaw Firms
Americans for Equal Opportunity has filed a new charge with the Equal Employment Opportunity Commission targeting a major legal industry diversity program and 14 prominent law firms. The complaint names Sponsors for
More
LGEN shares are drawing fresh attention from income-focused investors seeking reliable dividend returns in an uncertain market environment. Legal & General, the FTSE 100 insurer listed on the London Stock Exchange under
More
Warren Buffett has long been regarded as one of the most disciplined and clear-headed investors in the history of financial markets. His approach to investing during periods of fear and uncertainty has
More
The UK stock market has been shrinking for years, with fewer listed companies and reduced market capitalisation raising serious concerns among investors and analysts alike. London’s stock exchange has seen a notable
More
Coinbase’s UK chief executive says sweeping new Financial Conduct Authority rules will force non-compliant crypto firms out of the British market entirely. Keith Grose, UK chief executive of Coinbase, argued that the
More
Karyopharm Therapeutics has suffered a severe blow after its flagship drug selinexor, sold as Xpovio, failed to meet its primary endpoint in a Phase 3 endometrial cancer trial. The XPORT-EC-042 trial evaluated
More